Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Deals

WinHealth Pharma and Ferring Partner to Co-Promote Pentasa in China

Fineline Cube Jun 16, 2022

China-based Hong Kong WinHealth Pharma Group Ltd has entered into a new partnership with Switzerland-headquartered...

Company Deals

WuXi ATU Partners with Wugen to Accelerate NK Cell Therapy Development

Fineline Cube Jun 16, 2022

WuXi ATU, the gene and cell therapy-focused CTDMO unit of WuXi Apptec (SHA: 603259, HKG:...

Company Drug

Jiangsu Hengrui Medicine’s SHR4640 Receives NMPA Approval for Gout Trial

Fineline Cube Jun 16, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval from the National...

Company Drug

Beijing Aosaikang’s ASKG315 Receives NMPA Approval for Solid Tumor Trial

Fineline Cube Jun 16, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced that its clinical trial application for ASKG315,...

Company Deals

Jacobson Pharma Leads HKD 6 Million JV for Specialty Drug Distribution

Fineline Cube Jun 16, 2022

China-based Jacobson Pharma Corporation (HKG: 2633), Ban Loong Holdings Ltd (HKG: 0030), and JBM (Healthcare)...

Company Drug

Hansoh Pharmaceutical’s Ameile Accepted for UK Regulatory Review

Fineline Cube Jun 16, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a Marketing Authorization Application (MAA)...

Company Deals

MegaRobo Secures USD 300 Million in Series C Round Led by Goldman Sachs

Fineline Cube Jun 16, 2022

Beijing-based MegaRobo Technologies, a company applying robotics and artificial intelligence (AI) in the life sciences...

Policy / Regulatory

China Issues Monkeypox Diagnosis Guidelines Amid Global Outbreaks

Fineline Cube Jun 16, 2022

China’s National Health Commission (NHC) has formulated and released the “Monkeypox Diagnosis and Treatment Guidelines”...

Company Deals

Quoin Pharmaceuticals Partners with WinHealth for Rare Disease Treatments in Greater China

Fineline Cube Jun 16, 2022

US-based rare disease specialist Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) announced a licensing and distribution agreement...

Legal / IP Policy / Regulatory

US Bipartisan Bill Seeks to Regulate Investments in Chinese High-Tech Firms

Fineline Cube Jun 16, 2022

US senators are preparing a bipartisan bill that would require US investors targeting Chinese high-tech...

Company Drug

Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052

Fineline Cube Jun 15, 2022

China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...

Company Drug

Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends

Fineline Cube Jun 15, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...

Company Drug

Jiangsu Hengrui Medicine’s Hetrombopag Olamine Receives FDA Orphan Drug Designation for ITP

Fineline Cube Jun 15, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received orphan...

Company Legal / IP

WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake

Fineline Cube Jun 15, 2022

China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...

Company Drug

Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment

Fineline Cube Jun 15, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...

Company Drug

Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment

Fineline Cube Jun 15, 2022

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...

Company Deals

China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies

Fineline Cube Jun 15, 2022

China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement...

Company Drug

Clover Biopharmaceuticals Initiates SCB-219M Clinical Study for CIT Treatment

Fineline Cube Jun 15, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the first subject dosing in a Phase...

Drug

Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA

Fineline Cube Jun 15, 2022

China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it...

Company Deals

Ferring and I-Mab Expand Olamkicept Collaboration for Inflammatory Diseases

Fineline Cube Jun 14, 2022

Swiss pharmaceutical company Ferring Pharmaceuticals has announced a strategic collaboration with China’s I-Mab Inc. (NASDAQ:...

Posts pagination

1 … 703 704 705 … 707

Recent updates

  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.